menu
    • menu
    [{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":1.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Teijin Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":1.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Teijin Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Lonapegsomatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Teijin Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teijin Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teijin Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JTR-161","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teijin Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teijin Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TCK-276","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teijin Pharma \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Teijin Pharma \/ Parexel"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Teijin Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Teijin Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Teijin Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teijin Pharma \/ TransThera Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Teijin Pharma \/ TransThera Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Teijin Pharma

    Menu

    Teijin Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Teijin Pharma Receives Approval for Additional Indication for Xeomin in Japan

                            Details : Xeomin (incobotulinumtoxinA) is a SNAP-25 inhibitor protein drug candidate which is approved for the treatment of chronic sialorrhea.

                            Product Name : Xeomin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 26, 2025

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Recipient : Ascendis Pharma

                            Deal Size : $245.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

                            Details : Under the agreement, Teijin will receive exclusive license to further develop and commercialize TransCon hGH (lonapegsomatropin-tcgd), TransCon PTH, and TransCon CNP for endocrinology rare disease, in Japan.

                            Product Name : Skytrofa

                            Product Type : Hormone

                            Upfront Cash : $70.0 million

                            November 29, 2023

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Recipient : Ascendis Pharma

                            Deal Size : $245.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease

                            Details : Teijin will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize an investigational small molecule candidate for proteinuric kidney diseases. The candidate is believed to impact the pathogenesis of multiple kidney...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $30.0 million

                            March 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCK-276

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthr...

                            Details : TCK-276 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 29, 2022

                            Lead Product(s) : TCK-276

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin ® From Merz

                            Details : Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.

                            Product Name : Xeomin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 23, 2021

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate,Pioglitazone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited

                            Details : The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

                            Product Name : Liovel

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 01, 2021

                            Lead Product(s) : Alogliptin Benzoate,Pioglitazone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

                            Details : The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

                            Product Name : Liovel

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : TransThera Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

                            Details : Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 18, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : TransThera Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTR-161

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic H...

                            Details : JTR-161 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 29, 2020

                            Lead Product(s) : JTR-161

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMX-049

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

                            Details : TMX-049 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Nephropathies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 28, 2018

                            Lead Product(s) : TMX-049

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth